ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / IQV / earnings
INCY (84) MEDP (80) CRL (63) ICLR (71) ⌘ Pro Terminal →

IQVIA Holdings Inc. (IQV) Next Earnings Date & Expected ±6.8% Move

$267.33 -2.81% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $265.47

IQVIA Holdings Inc. (IQV) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY) →
ROARABLE C • HOLD / WATCH Cap $45.33B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IQV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, IQVIA Holdings Inc. (NYSE: IQV) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $267.33 (-2.81% 1D, market cap $45.33B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IQV ranks #132 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IQV compare to INCY and MEDP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), IQV carries a Roarable C (64/100 RQD), trailing P/E of 33.3x, gross margin of —, and ROIC of 9.4%. By comparison, INCY (Incyte Corp.) holds a A- grade (84/100 RQD, P/E 18.4x, ROIC 42.4%, cap $23.68B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IQV?
▼

Per IQV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478242), IQVIA Holdings Inc. generated $16.31B in revenue (+5.9% YoY), $1.36B in net income, and $1.92B in free cash flow against $29.94B in total assets and $13.88B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $265.46 (-0.70%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 11.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510064
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk D
Cash (13)Whales (18)SEC (10)Macro (10)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
$324 Bull$275 Base$214 Bear
📬 FREE IQV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IQV)Realized 20D OHLCV Swing Band: ±6.8%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY IQV SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (28% of score)

20D Institutional Volume Accumulation (±6.8% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 11.8% FCF Margin ($1.92B FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (55.7) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
56
Grade C$260.68+2.8% Next Q
Q2 (-2Q)
59
Grade C$267.85+1.4% Next Q
Q3 (-1Q)
61
Grade C$271.55-1.6% Next Q
Current
64
Grade C$267.33+1.1% Hist 90D α
Trajectory: C (56) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IQV Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, IQV faces multiple-compression risk if 33.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($266.69) or 200D SMA ($209.87) invalidates the momentum regime and cuts Target Base ($274.55) toward Bear Floor ($214.15).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IQV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IQV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 64%NO 36%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±6.8% Swing Band

±$18.18 Expected Swing
$249.15 (-6.8%)Spot $267.33$285.51 (+6.8%)
MODEL EARNINGS SETUP GAUGE

IQV Quantitative Pre-Earnings Setup: 64/100

Trailing EPS: $8.25 • YoY Revenue Growth: 5.9%

Model Bullish Setup (64/100)Model Risk Weight (36/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$16.31B$1.36B$1.92B52%
FY 20242024-12-31$15.40B$1.37B$2.02B52%
FY 20232023-12-31$14.98B$1.36B$1.47B52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating IQV & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on IQV
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IQV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +66.11%🛡️ HOLDING TREND SUPPORT
2026-11-02O $279.0H $279.0L $267.3C $267.3VOL 1.43M
RES: $333.3SUP: $265.1SMA50: $266.7SMA200: $209.9
$293.5$256.4$219.3$182.2$145.1RES $333.3SUP $265.1$267.32026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IQV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IQV Butterfly Map → + Track IQV →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
25.7%/yr Implied 5Y Growth

vs. +5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IQV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IQV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IQV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IQV)

Health Care Rank #132 of 1016 ⚔️ INCY vs IQV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IQV vs. INCY, MEDP, CRL, ICLR)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, IQVIA Holdings Inc. (IQV) ranks #132 by composite RQD confidence (64/100, grade C) and #43 by equity capitalization ($45.33B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 84/100 (A-) compared with IQV at 64/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IQV ACTIVE
IQVIA Holdings Inc.
C 64/100 33.3x — 9.4% -2.81% $45.33B Benchmark Subject
INCY
Incyte Corp.
A- 84/100 18.4x 92.8% 42.4% +3.07% $23.68B /incy-vs-iqv →
MEDP
Medpace Holdings Inc.
B+ 80/100 42.0x — 27.9% -3.77% $18.95B /medp-vs-iqv →
CRL
Charles River Laboratories International Inc.
C 63/100 — — 0.4% -4.44% $17.95B /crl-vs-iqv →
ICLR
ICON plc
B- 71/100 71.9x — 3.1% -1.91% $16.50B /iclr-vs-iqv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001478242

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IQVIA Holdings Inc. (IQV) reported GAAP revenue of $16.31B (+5.9% vs. FY2024 revenue of $15.40B , and +8.8% cumulative change since FY2023) , GAAP net income of $1.36B, operating cash flow of $2.65B, and free cash flow of $1.92B (-5.1% YoY). On the balance sheet, IQV closed FY2025 with $29.94B in total assets against $13.88B in total debt (Altman Z-Score: 2.22, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $16.31B $1.36B $2.65B $1.92B $29.94B $13.88B
FY2024 (FY) 2024-12-31 $15.40B $1.37B $2.72B $2.02B $26.90B $12.84B
FY2023 (FY) 2023-12-31 $14.98B $1.36B $2.15B $1.47B $24.93B $5.83B

3. IQV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, IQVIA Holdings Inc. (NYSE: IQV) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $267.33 (-2.81% 1D, market cap $45.33B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, IQV ranks #132 in composite RQD confidence.

How does IQV compare to INCY and MEDP in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), IQV carries a Roarable C (64/100 RQD), trailing P/E of 33.3x, gross margin of —, and ROIC of 9.4%. By comparison, INCY (Incyte Corp.) holds a A- grade (84/100 RQD, P/E 18.4x, ROIC 42.4%, cap $23.68B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (80/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.95B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IQV?

Per IQV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478242), IQVIA Holdings Inc. generated $16.31B in revenue (+5.9% YoY), $1.36B in net income, and $1.92B in free cash flow against $29.94B in total assets and $13.88B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IQV trading relative to its 50-day, 200-day, and 52-week technical levels?

IQV last traded at $267.33 (-2.81% on volume of 1,150,295 shares), positioning the stock +0.24% above its 50-day simple moving average ($266.69) and +27.38% above its 200-day simple moving average ($209.87). Across its 52-week range of $154.50 to $284.50, IQV sits at the 86.8% percentile with a 14-day RSI of 55.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.8% ($249.15 to $285.51).

IQV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is IQV's next earnings date?

Based on SEC filing cadence, IQVIA Holdings Inc. (IQV)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is IQV stock expected to move on earnings?

Volatility modeling currently projects a ±6.8% event move for IQV, spanning a range between $249.15 and $285.51.

Direct Sub-Reports: IQV RQD Cockpit IQV 12M Forecast IQV Earnings & Move IQV Dividends & DRIP IQV Insiders & 13F IQV Whale Options IQV Profit Sankey IQV News & Why
ROARABLE RATING BRIEF • RQD 64/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

IQV — IQVIA Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:11:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, IQV scores 64 out of 100, a letter grade of C, with the verdict "Roarable Hold — Fair / Balanced Risk-Reward." Across its five pillars: the Fundamental Cash Engine scores 13 of 20 (ROIC 9.4%; FCF yield 4.24%), suggesting cash generation that is adequate but not exceptional relative to the capital employed. Whale/13F Flow scores 18 of 20 (institutional accumulation and options positioning), the strongest pillar and a supportive signal for near-term demand. Insider Conviction scores 13 of 20 (SEC Form 4 and Congressional PTR cluster flow), a moderate reading. Macro Regime Fit scores 10 of 20 (Beta 1.16; sector sensitivity), indicating above-market sensitivity to broad moves. Forensic Balance Sheet scores 10 of 20 (Altman Z 2.22; Piotroski F 6/9; Debt/Equity 2.14), flagging leverage as the key constraint on the rating.

For a prospective investor, the picture is mixed: institutional positioning is a clear upside driver, while valuation (P/E TTM 33.3, EV/EBITDA 20.4) and elevated leverage limit margin for error. The rating frames the stock as balanced rather than compelling on fundamentals alone.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
275.06$45.33B33.33120.48.250%1.16$154.5 - $284.59.4%

Business

IQVIA Holdings Inc. is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Commercial Physical & Biological Resarch industry. Per the profile, the company carries a market capitalization of $45.3B. Source data does not describe its specific products, customers, or revenue mechanics beyond sector and industry classification.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$16310.0M$2182.0M$1360.0MN/A$1920.0M$1980.0M$13884.0M
FY 2024$15405.0M$2202.0M$1373.0MN/A$2022.8M$1702.0M$12838.0M
FY 2023$14984.0M$1977.0M$1358.0MN/A$1474.7MN/A$5834.0M

Revenue rose from $14984.0M (FY 2023) to $16310.0M (FY 2025), while net income was broadly flat across the three periods. Per the market data, the operating margin is 13.4%, the net margin 8.3%, and ROIC 9.4%. The Forensic Balance Sheet pillar cites an Altman Z-Score of 2.22 and a Piotroski F-Score of 6/9. Reported debt climbed from $5834.0M (FY 2023) to $13884.0M (FY 2025), and the source cites a Debt/Equity of 2.14.

Recent Catalysts & News Wire Analysis

  • A "CATALYST"-tagged item (GREEN light) cites a Seeking Alpha headline: "IQVIA gains as R&D Solutions drive Q3 beat," the only non-yellow signal in the feed.
  • A ChartMill item (YELLOW) references strong technical ratings and a possible breakout setup.
  • A GuruFocus item (YELLOW) notes the stock was up 3.5% but that GF Value indicates overvaluation.
  • Other wire items (Yahoo! Finance Canada, marketscreener.com, StockInvest.us) are general market-action and quote coverage.
  • Per the market data, the stock closed at 275.06, down 1.43% on volume of 1,430,079.
  • Butterfly Supply-Chain Graph: Not available in source data for supply-chain links; no butterfly links or proprietary signals are provided.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

The Butterfly Supply-Chain Graph lists supply chain as "NONE" with no butterfly links. Not available in source data for upstream or downstream dependencies, sector correlations, or second-order bottlenecks beyond the stated sector (Health Care) and industry classification.

Open Questions

  • What specific products, customers, and revenue segments drive the reported revenue of $16310.0M?
  • What explains the rise in reported debt from $5834.0M (FY 2023) to $13884.0M (FY 2025), and what are the maturity and interest terms?
  • Why is EPS reported as N/A across all periods, and what is the reconciled per-share earnings history?
  • What are the specific institutional and insider transactions underlying the Whale/13F and Insider Conviction pillar scores?
  • What supply-chain dependencies and sector correlations apply, given the Butterfly graph is empty?

IQV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IQVIA Holdings Inc. (IQV) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IQV Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IQV Bull vs. Bear Conversation Board — What's Your Call at $267.33?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IQV 🐻 50% BEARISH CONVICTION
1. Pick Your Side on IQV:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $297.06 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is IQV (C • RQD 64/100) a Buy at $275.06?

Welcome to the IQV (IQVIA Holdings Inc.) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (33.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $214.55 (-22.0%)
Spot @ $275.06

Pump the brakes on IQV — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on IQV, but look at what you are paying: 33.3x trailing P/E with tightening sector spreads. Unless IQVIA Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $330.07 (+20.0%)
Spot @ $275.06

IQV cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on IQV, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $275.06 (52-wk range $154.50 - $284.50), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%